INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRATED BIOPHARMA INC revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing [Member] | $42.39M | $51.68M | $48.57M | $48.28M | $54.09M | $61.84M | $51.33M | $48.44M | $42.08M | $45.10M | 96.6% | -18.0% |
| Other Nutraceutical Business [Member] | $1.48M | $2.67M | $1.75M | $2.40M | $2.16M | $1.72M | $1.44M | $1.54M | $1.38M | $1.47M | 3.4% | -44.4% |
| Branded Proprietary Products [Member] | – | – | – | – | – | – | – | $159.00K | $252.00K | $385.00K | – | – |
By product or service
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $35.23M | $43.63M | $42.34M | $42.62M | $46.52M | $54.39M | $44.30M | $43.17M | $37.24M | $37.67M | 80.3% | -19.2% |
| Non-US [Member] | $8.64M | $10.73M | $7.97M | $8.06M | $9.73M | $9.17M | $8.47M | $6.81M | $6.47M | – | 19.7% | -19.4% |
| International Customers [Member] | – | – | – | – | – | – | – | – | $6.47M | $9.28M | – | – |
| Europe and Canada [Member] | – | – | – | – | – | $9.17M | $8.47M | $6.81M | $6.47M | $9.28M | – | – |
From the segment and revenue-disaggregation notes of Integrated Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.